Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

R. Preston Mason, PH.D.

TitleLecturer on Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Tower-3-B, Cardiovascular
75 Francis St
Boston MA 02115
Phone617/732-8786
Fax617/975-0995

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mason RP, Kubant R, Jacob RF, Malinski P, Huang X, Louka FR, Borowiec J, Mizuno Y, Malinski T. Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers. Am J Hypertens. 2009 Nov; 22(11):1160-6.
    View in: PubMed
  2. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol. 2009 Aug; 54(2):123-8.
    View in: PubMed
  3. Self-Medlin Y, Byun J, Jacob RF, Mizuno Y, Mason RP. Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation. Biochim Biophys Acta. 2009 Jun; 1788(6):1398-403.
    View in: PubMed
  4. Contero A, Richer E, Gondim A, Mason RP. High-throughput quantitative bioluminescence imaging for assessing tumor burden. Methods Mol Biol. 2009; 574:37-45.
    View in: PubMed
  5. Chatterjee S, Ehrenshaft M, Bhattacharjee S, Deterding LJ, Bonini MG, Corbett J, Kadiiska MB, Tomer KB, Mason RP. Immuno-spin trapping of a post-translational carboxypeptidase B1 radical formed by a dual role of xanthine oxidase and endothelial nitric oxide synthase in acute septic mice. Free Radic Biol Med. 2009 Feb 15; 46(4):454-61.
    View in: PubMed
  6. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008 Oct; 21(10):1076-85.
    View in: PubMed
  7. McNulty H, Jacob RF, Mason RP. Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am J Cardiol. 2008 May 22; 101(10A):20D-29D.
    View in: PubMed
  8. Walter MF, Jacob RF, Bjork RE, Jeffers B, Buch J, Mizuno Y, Mason RP. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol. 2008 Mar 25; 51(12):1196-202.
    View in: PubMed
  9. Funovic P, Korda M, Kubant R, Barlag RE, Jacob RF, Mason RP, Malinski T. Effect of beta-blockers on endothelial function during biological aging: a nanotechnological approach. J Cardiovasc Pharmacol. 2008 Feb; 51(2):208-15.
    View in: PubMed
  10. Mason RP. Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Drugs. 2008; 68(7):885-900.
    View in: PubMed
  11. Mason RP, Kubant R, Heeba G, Jacob RF, Day CA, Medlin YS, Funovics P, Malinski T. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res. 2008 Aug; 25(8):1798-806.
    View in: PubMed
  12. Roberts WC, Black HR, Bakris GL, Mason RP, Giles TD, Sulkes DJ. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67.
    View in: PubMed
  13. Yuan C, O'Connell RJ, Jacob RF, Mason RP, Treistman SN. Regulation of the gating of BKCa channel by lipid bilayer thickness. J Biol Chem. 2007 Mar 9; 282(10):7276-86.
    View in: PubMed
  14. Mason RP, Walter MF, Day CA, Jacob RF. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell Biochem. 2007; 42:175-90.
    View in: PubMed
  15. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich). 2006 Dec; 8(12 Suppl 4):40-52.
    View in: PubMed
  16. Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol. 2006 Dec 4; 98(11A):34P-41P.
    View in: PubMed
  17. McNulty HP, Byun J, Lockwood SF, Jacob RF, Mason RP. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochim Biophys Acta. 2007 Jan; 1768(1):167-74.
    View in: PubMed
  18. Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich). 2006 Aug; 8(8 Suppl 2):31-8; quiz 40.
    View in: PubMed
  19. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol. 2006 Jul; 48(1):862-9.
    View in: PubMed
  20. Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem. 2006 Apr 7; 281(14):9337-45.
    View in: PubMed
  21. Mason RP, Walter MF, McNulty HP, Lockwood SF, Byun J, Day CA, Jacob RF. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol. 2006; 47 Suppl 1:S7-14.
    View in: PubMed
  22. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005 Dec 13; 112(24):3795-801.
    View in: PubMed
  23. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005 Dec; 118 Suppl 12A:54-61.
    View in: PubMed
  24. Mason RP. A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):489-501.
    View in: PubMed
  25. Jacob RF, Mason RP. Lipid peroxidation induces cholesterol domain formation in model membranes. J Biol Chem. 2005 Nov 25; 280(47):39380-7.
    View in: PubMed
  26. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005 Sep 5; 96(5A):11F-23F.
    View in: PubMed
  27. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004 Dec; 177(2):235-43.
    View in: PubMed
  28. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004 Nov 16; 44(10):1996-2002.
    View in: PubMed
  29. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004 Aug; 15(5):251-8.
    View in: PubMed
  30. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004 Jun 1; 109(21 Suppl 1):II34-41.
    View in: PubMed
  31. Cenedella RJ, Jacob R, Borchman D, Tang D, Neely AR, Samadi A, Mason RP, Sexton P. Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor. J Lipid Res. 2004 Jul; 45(7):1232-41.
    View in: PubMed
  32. Chen YR, Chen CL, Chen W, Zweier JL, Augusto O, Radi R, Mason RP. Formation of protein tyrosine ortho-semiquinone radical and nitrotyrosine from cytochrome c-derived tyrosyl radical. J Biol Chem. 2004 Apr 23; 279(17):18054-62.
    View in: PubMed
  33. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003 Dec; 23(12):2155-63.
    View in: PubMed
  34. Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation. 2003 May 6; 107(17):2270-3.
    View in: PubMed
  35. Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis. 2003; 16 Suppl 3:11-7.
    View in: PubMed
  36. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002 Dec; 165(2):191-9.
    View in: PubMed
  37. Mason RP, Jacob RF. X-ray diffraction analysis of membrane structure changes with oxidative stress. Methods Mol Biol. 2002; 196:69-78.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Mason's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (220) concept(s)
_
Co-Authors
See all (1) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_